Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such delivery device

• US 10,610,407 B2
• Filed: 11/20/2017
• Issued: 04/07/2020
• Est. Priority Date: 07/02/2004
• Status: Active Grant

• Current Assignee: Mati Therapeutics, Inc
• Original Assignee: Mati Therapeutics, Inc
• Inventors: Lazar, Eliot
• Primary Examiner(s): Mendez, Manuel A
• Application Number:
  US15/817,649
• Publication Number:
  US 20180071142A1
• Time in Patent Office: 869 Days
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00772 Apparatus for restoration of tear ducts

Abstract

A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.

Claims

1. A device for delivering a treatment medium to an eye, comprising:

a biocompatible polymer capsule comprising a core containing a therapeutic medium immobilized with a biocompatible matrix and a surrounding jacket that permits diffusion of the therapeutic medium to the eye; and

,

wherein the delivery device is configured and arranged to occlude or plug the punctum.

2. The device of claim 1, wherein the biocompatible matrix comprises a hydrogel.

3. The device of claim 1, wherein the biocompatible matrix comprises biodegradable polymers.

4. The device of claim 1, wherein the jacket is a semi-permeable membrane.

5. The device of claim 1, wherein the jacket comprises polymers or polymer blends of polyacrylates, acrylic copolymers, polyvinylidenes, polyvinyl chloride copolymers, polyurethanes, polystyrenes, polyamides, cellulose acetates, cellulose nitrates, polysulfones, polyether sulfones, polyphosphazenes, polyacrylonitriles, poly(acrylonitrile/covinyl chloride), or combinations thereof.

6. The device of claim 1, wherein the treatment medium comprises a prostaglandin, anti-inflammatories, non-steroidal anti-inflammatories or immunosuppressive agents.

7. The device of claim 6, wherein the treatment medium comprises dexamethasone or a corticosteroid.

8. The device of claim 1, wherein the treatment medium is selected from the group consisting of thrombin inhibitors;

anti-thrombogenic agents;

thrombolytic agents;

fibrinolytic agents;

vasospasm inhibitors;

calcium channel blockers;

vasodilators;

antihypertensive agents;

antimicrobial agents;

inhibitors of surface glycoprotein receptors;

antiplatelet agents;

anti-mitotics;

microtubule inhibitors;

anti-secretory agents;

active inhibitors;

remodeling inhibitors;

antisense nucleotides;

anti-metabolites;

anti-proliferatives;

anticancer chemotherapeutic agents;

anti-inflammatories;

non-steroidal anti-inflammatories;

anti-allergenics;

antiproliferative agents;

decongestants;

miotics, anticholinesterase;

anti-neoplastics;

immunological drugs;

hormonal agents;

immunosuppressive agents;

growth hormone antagonists;

growth factors;

inhibitors of angiogenesis;

dopamine agonists;

radiotherapeutic agents;

peptides;

proteins;

enzymes;

extracellular matrix components;

ACE inhibitors;

free radical scavengers;

chelators;

antioxidants;

anti-polymerases;

photodynamic therapy agents;

gene therapy agents;

prostaglandins;

anti-prostaglandins;

prostaglandin precursors and combinations thereof.

9. The device of claim 1, wherein the treatment medium is delivered in a controllable manner over a predetermined time period directly to the eye.

10. The device of claim 1, wherein the treatment medium is retained in proximity to the external surface of the eye and is prevented from leaving the treatment site via the blocked punctum.

11. A method for delivering a treatment medium to an eye, comprising:

providing a delivery device according to claim 1 comprising a treatment medium; and

inserting the delivery device into a punctum of the eye, whereby the treatment medium is delivered to the eye.

12. The method of claim 11, wherein the treatment medium is formulated as a sustained release formulation.

13. The method of claim 11, wherein the treatment medium is a treatment for pre- and post-operative inflammation or pain, glaucoma, inflammation, infections, or dry eye.